Breast cancer drug may hold key to tackling most deadly type of melanoma
23 July 2019
Barbara Holland tried everything to stop headaches for months before her doctor sent her for an MRI. Her scans showed a tumour in her sinus
Mucosal melanoma, which occurs on the inner surfaces of the body such as the mouth, nose and anogenital region and
Now, an Australian-led international team of researchers has discovered that a drug traditionally used to treat a
The international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has uncovered the diverse genetic drivers for mucosal melanoma
Lead study author Professor Richard Scolyer, Co-Medical Director Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital says the study allowed researchers to not only look for new drug targets, but
“We now understand the genetic drivers of mucosal
“The ramifications of this study are immense and are critical in us reaching our goal of zero deaths from melanoma.”
Published online at Nature Communications, the study detailed the genetic analysis of 67 mucosal melanoma tumours from patients from Australia, China, the United States and Europe. Using both whole-genome sequencing and whole-
“While advancements in treatment have drastically improved survival outcomes for cutaneous (or skin) melanoma patients, those treatments do not work as well for mucosal melanoma patients,” Professor Scolyer added.
“But now we can build our treatment arsenal for this group of patients
The study also found
“I’m one of the lucky ones,” said Barbara.
“This news is so exciting for other mucosal patients and their families.
While rare in Western populations like in Australia, where it makes up less than 2% of all melanoma cases, mucosal melanoma makes up a third
A previous study also coming from the Australian Melanoma Genome Project found that mucosal melanoma
There are no known risk factors for mucosal melanoma, making prevention strategies difficult. It
“The next exciting step is for Melanoma Institute Australia to develop a clinical trial to test classes of drugs and their effectiveness for treating mucosal melanoma,” said study author Professor Georgina Long, Co-Medical Director Melanoma Institute Australia The University of Sydney and Royal North Shore Hospital
“This is the new frontier in melanoma treatment, with very real benefits for patients internationally, and we are proud to be leading the world in saving lives.”
Barbara is no longer on treatment and comes to MIA for three monthly scans.
“It’s amazing to know that there could soon be new treatments for this horrible disease. I think the best part about this discovery is that it gives hope,” said Barbara.
Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.
Promising young MIA researcher conferred with University of Sydney PhD.
Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Honouring the exceptional impact of his work on communities around the world.
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
Awarded for their life-saving discoveries transforming melanoma patient care.
National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment
Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.
Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.
MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.
New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.
With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever.
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Read more about the wonderful MIA community fundraising initiatives held recently.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.